HomeCompareOCLCF vs ABBV

OCLCF vs ABBV: Dividend Comparison 2026

OCLCF yields 2.20% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCLCF wins by $97.70M in total portfolio value· pulled ahead in Year 4
10 years
OCLCF
OCLCF
● Live price
2.20%
Share price
$59.90
Annual div
$1.32
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$97.80M
Annual income
$89,953,885.30
Full OCLCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — OCLCF vs ABBV

📍 OCLCF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCLCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCLCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCLCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCLCF
Annual income on $10K today (after 15% tax)
$187.18/yr
After 10yr DRIP, annual income (after tax)
$76,460,802.51/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, OCLCF beats the other by $76,439,746.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCLCF + ABBV for your $10,000?

OCLCF: 50%ABBV: 50%
100% ABBV50/50100% OCLCF
Portfolio after 10yr
$48.95M
Annual income
$44,989,328.53/yr
Blended yield
91.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

OCLCF
No analyst data
Altman Z
8.8
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCLCF buys
0
ABBV buys
0
PoliticianChamberTickerTypeAmountDate
Zoe Lofgren🏢 House$OCLCF▼ Sell$15,001 - $50,0002023-05-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCLCFABBV
Forward yield2.20%3.06%
Annual dividend / share$1.32$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$97.80M$102.3K
Annual income after 10y$89,953,885.30$24,771.77
Total dividends collected$97.18M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OCLCF vs ABBV ($10,000, DRIP)

YearOCLCF PortfolioOCLCF Income/yrABBV PortfolioABBV Income/yrGap
1$11,140$440.43$11,550$430.00$410.00ABBV
2$12,837$917.13$13,472$627.96$635.00ABBV
3$15,711$1,975.38$15,906$926.08$195.00ABBV
4← crossover$21,330$4,518.91$19,071$1,382.55+$2.3KOCLCF
5$34,290$11,467.23$23,302$2,095.81+$11.0KOCLCF
6$71,148$34,457.60$29,150$3,237.93+$42.0KOCLCF
7$209,765$133,635.89$37,536$5,121.41+$172.2KOCLCF
8$960,887$736,438.84$50,079$8,338.38+$910.8KOCLCF
9$7,333,699$6,305,549.74$69,753$14,065.80+$7.26MOCLCF
10$97,800,943$89,953,885.30$102,337$24,771.77+$97.70MOCLCF

OCLCF vs ABBV: Complete Analysis 2026

OCLCFStock

Oracle Corporation Japan engages in the development and sale of software and hardware products and solutions in Japan. The company operates through three segments: Cloud and License, Hardware Systems, and Services. It sells software solutions, such as relational database management software, middleware, and applications; hardware, including servers, storage devices, and network devices for use in building and operating IT environments, such as cloud computing environments; and cloud services through Internet and other networks, as well as provides software license update rights and technical support. The company also offers technical support, maintenance, and repair of hardware products; and consulting, customer support, and education services. In addition, it provides Oracle database, Java, Linux, and MySQL software solutions; and Oracle cloud infrastructure, which include compute, storage, networking, analysis, application development, cloud database, content management, integration, cloud marketplace and management, and governance services, as well as security, identity, and compliance solutions. Further, the company offers cloud applications, such as enterprise resource planning, enterprise performance management, supply chain and manufacturing, human capital management, and advertising and customer experience cloud application solutions, as well as NetSuite and on-premise application products and solutions; and marketing, sales, and services. It serves automotive, communications, construction and engineering, consumer goods, education and research, financial services, food and beverage, healthcare, technology, hospitality, industrial manufacturing, life sciences, media and entertainment, public sector, retail, and utilities sectors. The company was founded in 1985 and is headquartered in Tokyo, Japan. Oracle Corporation Japan is a subsidiary of Oracle Japan Holding Inc.

Full OCLCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this OCLCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCLCF vs SCHDOCLCF vs JEPIOCLCF vs OOCLCF vs KOOCLCF vs MAINOCLCF vs JNJOCLCF vs MRKOCLCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.